Skip to content
    Leaps by Bayer logo

    Leaps by Bayer

    Leverkusen, GermanyFounded 2015
    leaps.bayer.comLinkedIn
    Biotech & Life SciencesFood & AgricultureHealthcare

    Leaps by Bayer is the corporate venture capital and impact investment arm of Bayer AG, investing in paradigm-shifting breakthroughs across life sciences, health, and agriculture. It backs early-to-late-stage companies pursuing fundamental scientific advances.

    39% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (4 deals in the last 12 months vs 6 prior). Average disclosed round size is $69.0M (across 110 rounds with reported amounts).

    Find people at Leaps by Bayer on Goldilocks AI

    Portfolio

    85

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    4

    Team

    SR

    Sören Roth

    Global HR Business Partner

    BK

    Brendan Kelly

    Senior Director of Health Venture Investments

    DB

    Denise Boehme

    Director Portfolio Strategy & Reporting

    KR

    Karyn Riegel

    Deputy Director of Brand & Community Engagement

    KP

    Kira Peikoff

    Deputy Director Communications

    SO

    Sara Olson

    Senior Director of Agriculture Venture Investments

    SN

    Steven Neier

    Senior Director, Healthcare Venture Investments

    AG

    André Guillaume

    VP / Head of Brand & Community Engagement

    DN

    Derek Norman

    Vice President, Venture Investments

    PA

    Paimun Amini

    VP of Agriculture Venture Investments

    NP

    Neele Piekarz

    Brand & Community Engagement Associate

    RD

    Rakhshita Dhar

    Healthcare venture investments

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    130 investments
    CompanyRoundAmountDate
    SSouffle TherapeuticsSeries A—Aug 2026
    Nava Therapeutics logoNava TherapeuticsUnknown$89MJul 2026
    Sabanto logoSabantoSeries B—Jul 2026
    Sabanto logoSabantoSeries B—Jul 2026
    SonoThera logoSonoTheraSeries B$125MJan 2026
    Celea Therapeutics logoCelea TherapeuticsSeed$180MJan 2026
    LLeafSeries B$13MJan 2026
    eGenesis logoeGenesisSeries D$191MAug 2025
    NuCicer logoNuCicerSeries A$11.5MJul 2025
    Indapta Therapeutics logoIndapta TherapeuticsUnknown$22.5MDec 2024
    One bio logoOne bioSeries A$27MDec 2024
    Nuvig Therapeutics logoNuvig TherapeuticsSeries B$161MDec 2024
    Senti Bio logoSenti BioUnknown$47.6MDec 2024
    EarthOptics logoEarthOpticsSeries C—Nov 2024
    Pairwise logoPairwiseSeries C$40MSep 2024
    Transcarent logoTranscarentSeries D$126MMay 2024
    Summer Health logoSummer HealthSeries A$11.7MApr 2024
    Capstan Therapeutics logoCapstan TherapeuticsSeries B$175MMar 2024
    Capstan logoCapstanSeries B$175MMar 2024
    9am.health logo9am.healthSeries A$9.5MFeb 2024
    NextPoint Therapeutics logoNextPoint TherapeuticsSeries B$42.5MFeb 2024
    Sudo Biosciences logoSudo BiosciencesSeries B$147MJan 2024
    Sudo logoSudoSeries B$147MJan 2024
    Transcarent logoTranscarentSeries D$126MJan 2024
    one.bio logoone.bioSeries A$27MJan 2024
    Page 1 of 6

    Top Co-Investors

    Alexandria Venture Investments21 shared
    Polaris Partners18 shared
    ARCH Venture Partners16 shared
    General Catalyst14 shared
    Bayer12 shared
    Samsara BioCapital11 shared
    RA Capital Management9 shared
    Timefolio Capital8 shared
    S2G Ventures8 shared
    Novartis Venture Fund7 shared
    Maverick Ventures7 shared
    Mirae Asset7 shared
    Mubadala Ventures7 shared
    Khosla Ventures7 shared
    Chan Zuckerberg Initiative7 shared
    Temasek Holdings (Private) Limited7 shared
    Sanofi Ventures7 shared
    Alta Partners7 shared
    OrbiMed6 shared
    Sofinnova Partners6 shared

    Last updated: 20 October 2026